Uncategorized

JD.com Annual Active Customer Accounts For 2021 Increased 29%

Annual active customer accounts4 increased by 29.0% to 499.8 million in the twelve months ended March 31, 2021 from 387.4 million in the twelve months ended March 31, 2020.

byBill Haddad

May 19, 2021

1 minute read

Annual active customer accounts4 increased by 29.0% to 499.8 million in the twelve months ended March 31, 2021 from 387.4 million in the twelve months ended March 31, 2020.

Societe Generale Downgrades Air Products & Chemicals to Hold, Announces $340 Price Target

By Benzinga Newsdesk

Today, 6:25 AM

Societe Generale analyst Peter Clark downgrades Air Products & Chemicals (NYSE:APD) from Buy to Hold and announces $340 price target.

APD

HC Wainwright & Co. Reiterates Buy on Alto Ingredients, Maintains $10 Price Target

By Benzinga Newsdesk

Today, 6:25 AM

HC Wainwright & Co. analyst Amit Dayal reiterates Alto Ingredients (NASDAQ:ALTO) with a Buy and maintains $10 price target.

ALTO

Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug

By Ragothaman Srinivasan

Today, 6:25 AM

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang Bio’s (NASDAQ: MBIO) lead drug MB-106 for the treatment of Waldenstrom macroglobulinemia (WM), a rare type of B-cell non-Hodgkin lymphoma (B-NHL).

MBIO

IPOs
News

Citius Pharmaceuticals, Inc. Announces Intention To Spinoff Late-Stage Oncology Asset, I/ONTAK, Into A New Standalone Publicly Traded Company

By Bill Haddad

Today, 6:25 AM

IPO with distribution of shares to Citius shareholders planned for 2H 2022 Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR) CRANFORD, N.J., May 25,

CTXR

JD.com Annual Active Customer Accounts For 2021 Increased 29%

Related Posts

Societe Generale Downgrades Air Products & Chemicals to Hold, Announces $340 Price Target

HC Wainwright & Co. Reiterates Buy on Alto Ingredients, Maintains $10 Price Target

Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug

Citius Pharmaceuticals, Inc. Announces Intention To Spinoff Late-Stage Oncology Asset, I/ONTAK, Into A New Standalone Publicly Traded Company